Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood test replace the annoying 24-Hour urine collection for tumor diagnosis?

NCT ID NCT02826928

Diagnosis Sponsor: CHU de Reims Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 116 people with small-intestine neuroendocrine tumors to see if a blood test or a shorter urine collection could replace the standard 24-hour urine test for diagnosis. The goal was to find a simpler, equally accurate way to measure a key tumor marker called 5HIAA. Results may lead to easier and faster testing for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

116 people

The number who actually took part.

Started

Oct 2016

Finished

Jun 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Histologically proven small-intestine neuroendocrine tumors, at initial diagnosis or during the follow-up * Irritable bowel syndrome, diagnosed following Rome III criteria, who had an ileo-colonoscopy and an abdominal CT-scan within the 12 last months * Age \> 18 years * No antitumor treatment within the last three months excepted somatostatin analogs * Ability of understanding and approving the study protocol and of providing written consent * Affiliation to the French Health Social System Exclusion criteria * Small-intestine neuroendocrine tumor in remission (no detectable disease) * Other malignancies than small-intestine neuroendocrine tumors (excepted if in remission for more than 2 years) * Kidney insufficiency (MDRD \< 60/min) * Urinary incontinency or inability to collect urines * Any antitumor treatment within the last three months excepted somatostatin analogs * Inability to interrupt treatments interfering with 5HIAA dosage * Pregnancy * Patients under law protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small-intestine neuroendocrine tumors (carcinoid tumors) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoid tumor small intestine neuroendocrine tumor, well differentiated, low or intermediate grade

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small-intestine neuroendocrine tumors (carcinoid tumors)

Contacts and locations

Locations

  • Chu Reims

    Reims, 51092, France